Bosutinib (SKI-606)

Licensed by Pfizer Catalog No.S1014

Bosutinib (SKI-606) Chemical Structure

Molecular Weight(MW): 530.45

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • A,IC50 of Bosutinib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. The effect of inhibitors is presented as the percentage of ANDV-induced permeability of inhibitor-treated monolayers 3 days postinfection and 30 min post-VEGF and FITC-dextran addition. B, VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for Fig. 1 at indicated times in the presence or absence of Bosutinib .

    J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck.

    Both parental and HR cell lines were treated with bosutinib (0.01, 0.1, and 1 μmol/L) for 24 hours. Src-related signaling pathway molecules were then analyzed.

    Mol Cancer Ther, 2017, 16(6):1145-1154. Bosutinib (SKI-606) purchased from Selleck.

  • SFK inhibitors abrogate tyrosine phosphorylation associated with sperm capacitation. Mouse sperm were incubated in the absence or in the presence of SKI606 for 60 min in capacitating (cap, with HCO3) or non-capacitating media (NC, without HCO3). Western blot analyses were performed withanti-pY antibodies.

    J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck.

    Abl kinase phosphorylates MNRR1 in vivo. (A) K562 cells harboring the constitutively active BCR-ABL kinase when treated with 100 nM Bosutinib for 24 h show a reduction in MNRR1 phosphorylation. Lysates from vehicle and Bosutinib treated cells were immunoprecipitated using the anti-phosphotyrosine antibody and analyzed for the levels of MNRR1 in the precipitate. The IgG levels are also shown for an equal pull-down. Bosutinib efficacy was confirmed using antibodies against phospho-Abl kinase and phospho-STAT5, a downstream target of Abl kinase. Tubulin was used as a loading control. (B) Bosutinib treatment reduces the levels of phosphorylated proteins only. The total protein levels (Abl kinase and MNRR1) in vehicle and Bosutinib treated cells were similar. (C) Levels of Abl kinase in the WT and Abl kinase deficient MEFs (Abl−/− MEFs). The doublet is caused by the presence of a non-specific band [28]. (D) The level of oxygen consumption in WT MEFs transfected with either WT or phosphomimetic Y99E mutant MNRR1. Oxygen consumption was measured in intact cells on a Seahorse Bioanalyzer. (E) Y99E mutant MNRR1 stimulates oxidative phosphorylation better than WT MNRR1 in Abl deficient MEFs (Abl−/− MEFs) as measured by intact cellular oxygen consumption. (F) Bosutinib also inhibits BCR-Abl kinase in the mitochondrial fraction. NDUFS3 was used as a mitochondrial marker and GAPDH as a cytoplasmic marker to evaluate purity of the fractions. (G) K562 cells treated with Bosutinib, which show a reduction in the level of MNRR1 tyrosine phosphorylation (A), also have a reduction in the levels of oxygen consumption. (H) MNRR1 is not phosphorylated in the Abl−/− MEFs. WT and Abl−/− cellular lysates were immunoprecipitated with the anti-phosphotyrosine antibody and probed for the presence of MNRR1. The total levels of MNRR1 in the WT and Abl−/− MEFs were similar.

    Biochim Biophys Acta, 2017, 1864(2):440-448. Bosutinib (SKI-606) purchased from Selleck.

  • Rescue ofPKAand tyrosine phosphorylation by Ser/Thr phosphatase inhibitors. A and B, spermwere incubated in capacitating medium supplemented with SFK inhibitors and different concentrations of okadaic acid (OA) (A) or calyculin-A (B), before immunodetection of p-PKA substrates (clone 100G7E). C and D, PVDF membranes used in A and B were stripped as described and used for Western blot immunodetection with anti-PY antibodies (clone 4G10).

    Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets
Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
1 nM 1.2 nM
In vitro

Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NB7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH5NG9KSzVyPUCuNFgzOzFiIN88US=> MnHOV2FPT0WU
SW756 NGHUe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVewbVhGUUN3ME2wMlE1ODJ2IDFOwG0> NFzh[HRUSU6JRWK=
CTV-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\tPWNKSzVyPUCuNVY{QThiIN88US=> Ml[0V2FPT0WU
HSC-4 NYPQdYRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LUSGlEPTB;MD6xO|E2QCBizszN NFHRN3dUSU6JRWK=
LAMA-84 NFTSfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\US3FKSzVyPUCuNlg3PjRiIN88US=> M4f3[HNCVkeHUh?=
KU812 NUHSbpQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG2WFBpUUN3ME2wMlM1ODZ6IDFOwG0> Mlu3V2FPT0WU
HCC1806 M3fs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe5SVRKSzVyPUCuN|UzOTZiIN88US=> Ml2yV2FPT0WU
DOK MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fFOWlEPTB;MD6zO|c5PiBizszN Mk\jV2FPT0WU
NCI-H209 NXfRVIdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\qOWlEPTB;MD60NFgxQCBizszN NYq3PIt4W0GQR1XS
EoL-1-cell NIHkXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwNEG1O|YhKM7:TR?= NV3td5lPW0GQR1XS
H9 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNEO0OlQhKM7:TR?= NXLxb|M5W0GQR1XS
EM-2 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\oUZBKSzVyPUCuOFM5QSBizszN Mnf3V2FPT0WU
NCI-H292 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq2TWM2OD1yLkS0NVA5KCEQvF2= NE\ZSlJUSU6JRWK=
697 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PXXGlEPTB;MD60OVY{OyBizszN MYLTRW5ITVJ?
BHT-101 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4VGlEPTB;MD60OlU6KCEQvF2= MknHV2FPT0WU
BE-13 M3jHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjiTWM2OD1yLkS4OVczKCEQvF2= NG[5SZpUSU6JRWK=
RS4-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmwTWM2OD1yLkS4OVg1KCEQvF2= M4LVO3NCVkeHUh?=
IGROV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnsNlZKSzVyPUCuOFg4QTdiIN88US=> MkLSV2FPT0WU
KE-37 NHrOWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS2WIxXUUN3ME2wMlQ6PTB7IDFOwG0> NVzKbXRqW0GQR1XS
BV-173 NEfifYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjMTWM2OD1yLkWwO|kzKCEQvF2= NIPLRVRUSU6JRWK=
MEG-01 NEH0dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwNUGyNVQhKM7:TR?= NVm2XlJ1W0GQR1XS
LB2241-RCC NWDoeZVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX4VFlKSzVyPUCuOVM4OThiIN88US=> M3:0W3NCVkeHUh?=
ACHN M4D0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDlb|lsUUN3ME2wMlU1ODZ7IDFOwG0> MVTTRW5ITVJ?
CTB-1 NH;jOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36yR2lEPTB;MD61OFgzKCEQvF2= MYnTRW5ITVJ?
HT-1080 NHvvZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ucGZSUUN3ME2wMlU2OzR7IDFOwG0> NGX1SIhUSU6JRWK=
CHL-1 M3T1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fMUGlEPTB;MD61OVQ3PSBizszN Ml\WV2FPT0WU
EW-3 NYe2R3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof4TWM2OD1yLkW1PVM2KCEQvF2= MX3TRW5ITVJ?
ES1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrqdFhKSzVyPUCuOlc1QThiIN88US=> M4DSfnNCVkeHUh?=
KASUMI-1 M2O1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrFTWM2OD1yLkeyN|MhKM7:TR?= M{TrbnNCVkeHUh?=
SW13 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TmfWlEPTB;MD63N|c6QCBizszN MX\TRW5ITVJ?
A3-KAW MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\qS2lEPTB;MD63PVIxQCBizszN MX\TRW5ITVJ?
LB771-HNC NIDu[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixTmhwUUN3ME2wMlg{OTB2IDFOwG0> NVWzc21pW0GQR1XS
OC-314 M2n4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fnfGlEPTB;MD64Olk3PSBizszN MoroV2FPT0WU
MLMA MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwOUC2O|UhKM7:TR?= NFzTTYlUSU6JRWK=
KARPAS-45 M2Doe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwOUK0OlYhKM7:TR?= MlTYV2FPT0WU
CAL-27 M{XYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXaTWM2OD1yLkmyPVA3KCEQvF2= M4XUXHNCVkeHUh?=
SK-NEP-1 M4rTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwOUeyOFghKM7:TR?= NYfpWIZ5W0GQR1XS
COR-L105 M3LVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPNVYlKSzVyPUGuNFA{QTRiIN88US=> M4fqSXNCVkeHUh?=
TI-73 M3nGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnVTGFKSzVyPUGuNFE3PSBizszN NGfnTWVUSU6JRWK=
JVM-3 M1jucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrLVmFKSzVyPUGuNFUxOTdiIN88US=> MUfTRW5ITVJ?
HAL-01 NXHhVZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorpTWM2OD1zLkC4PFEhKM7:TR?= MlXvV2FPT0WU
QIMR-WIL Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwMEmwOVghKM7:TR?= Mk\6V2FPT0WU
HSC-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFwMUG3PFMhKM7:TR?= MX\TRW5ITVJ?
KY821 NFf0V3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUntflNoUUN3ME2xMlE{OzVzIDFOwG0> NXfOU4ZRW0GQR1XS
5637 M3;sUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zuRWlEPTB;MT6xN|gxOyBizszN NEj2XVlUSU6JRWK=
CAL-33 NGO3RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUntRZZ{UUN3ME2xMlE6OzB{IDFOwG0> MoLUV2FPT0WU
ES4 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwMkC3PUAh|ryP MmTjV2FPT0WU
BHY NGW4d4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6xXWZuUUN3ME2xMlIzQDl{IDFOwG0> M{HXdXNCVkeHUh?=
LB1047-RCC M2faemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwMkO3PFUhKM7:TR?= NF3ld25USU6JRWK=
H4 M4rJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\2[GpKSzVyPUGuNlQzPTViIN88US=> MYLTRW5ITVJ?
RPMI-8866 NFqyWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof2TWM2OD1zLkK2NVA3KCEQvF2= M2D4bHNCVkeHUh?=
HO-1-N-1 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\P[5RKSzVyPUGuNlY{PjliIN88US=> NUi5Z2huW0GQR1XS
BB30-HNC NHLHc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnPU2dKSzVyPUGuNlg4OTRiIN88US=> M{LxenNCVkeHUh?=
PC-14 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwMkmyNFUhKM7:TR?= MmT1V2FPT0WU
NUGC-3 M1XyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHETWM2OD1zLkK5N|U3KCEQvF2= MYPTRW5ITVJ?
A4-Fuk NEjHcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mwXGlEPTB;MT6zNFcxPCBizszN NILwdItUSU6JRWK=
MHH-NB-11 MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHHSmZRUUN3ME2xMlMyOzh|IDFOwG0> NF71U|hUSU6JRWK=
KOSC-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjldG9KSzVyPUGuN|E4PzViIN88US=> NHHpTIdUSU6JRWK=
A498 M{LJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLrUGpGUUN3ME2xMlQxOTF|IDFOwG0> NUD3UopzW0GQR1XS
KG-1 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjETWM2OD1zLkSxNlc{KCEQvF2= M2DkTXNCVkeHUh?=
DEL MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTaTWM2OD1zLkSzOlU4KCEQvF2= M1PW[HNCVkeHUh?=
EW-16 NWqzWo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwNEO5O|MhKM7:TR?= MmTqV2FPT0WU
BPH-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwNES4NFUhKM7:TR?= MlXqV2FPT0WU
JAR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwNEmzOkAh|ryP M{TXWHNCVkeHUh?=
J-RT3-T3-5 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwNUG3NlIhKM7:TR?= M2nSfXNCVkeHUh?=
A375 NEPVeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1zLkWxO|czKCEQvF2= NGHYVHJUSU6JRWK=
SW954 NWPWNlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHScWFiUUN3ME2xMlU2ODB5IDFOwG0> MmfFV2FPT0WU
Ca9-22 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjRTWM2OD1zLkW2NlYhKM7:TR?= MmjEV2FPT0WU
D-566MG NHjaZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwNUexOVUhKM7:TR?= NGHOSohUSU6JRWK=
SCC-15 NFK5OFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7HOoZ6UUN3ME2xMlYyQDB2IDFOwG0> NFzrdIRUSU6JRWK=
HD-MY-Z NYTGTYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLZZlKSzVyPUGuOlM2QDRiIN88US=> MnfvV2FPT0WU
HT-1376 M{nRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWzXHM5UUN3ME2xMlY1OzZiIN88US=> NFrsdm9USU6JRWK=
CAL-54 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwNkW3NFkhKM7:TR?= MYrTRW5ITVJ?
ONS-76 NXu3NJJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUThO5FjUUN3ME2xMlY4PTVzIDFOwG0> MUfTRW5ITVJ?
EFO-27 NV61XWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M364RmlEPTB;MT62PFkzKCEQvF2= MWHTRW5ITVJ?
769-P NInsN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Lv[2lEPTB;MT62PVU6PiBizszN NVLSSYE6W0GQR1XS
MV-4-11 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHpPYQ5UUN3ME2xMlY6QDV4IDFOwG0> M2KwNXNCVkeHUh?=
NKM-1 M3\zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnZdo5KSzVyPUGuO|E5ODJiIN88US=> NGjhZW1USU6JRWK=
LOXIMVI NYXTclE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK3TWM2OD1zLke0OVk6KCEQvF2= MWjTRW5ITVJ?
KYSE-140 NIGyOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwN{W2OVUhKM7:TR?= MnTyV2FPT0WU
ES5 NHu4RZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DXVGlEPTB;MT64Olc1PyBizszN NFfLVoZUSU6JRWK=
BB65-RCC NXnnTWtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PRbWlEPTB;MT64PVg1QSBizszN NWrWXmJxW0GQR1XS
HN NYrtellyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXnbIN5UUN3ME2xMlg6QDd2IDFOwG0> M2HRV3NCVkeHUh?=
A101D M3vhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTPb3hKSzVyPUGuPVM3OjhiIN88US=> NEnESoRUSU6JRWK=
LoVo MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnrd5ZKSzVyPUGuPVc3PzliIN88US=> M4G5dXNCVkeHUh?=
NCI-H526 M2rxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfYbm05UUN3ME2xMlk6OzJ3IDFOwG0> MVjTRW5ITVJ?
NCI-H1693 M1zYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDFVGdKSzVyPUGuPVk5QDhiIN88US=> M{[zXHNCVkeHUh?=
OVCAR-4 M4m4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7IWWU4UUN3ME2yMlAxPDN3IDFOwG0> MXLTRW5ITVJ?
SK-HEP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPPdnpKSzVyPUKuNFA4PDViIN88US=> Mof3V2FPT0WU
C2BBe1 M4q5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\iTWM2OD1{LkCzN|czKCEQvF2= MV3TRW5ITVJ?
MEL-JUSO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJwMES0OlQhKM7:TR?= M{jwe3NCVkeHUh?=
MOLT-16 M4r3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPLTWM2OD1{LkC3NFU5KCEQvF2= NYG2NJpFW0GQR1XS
NBsusSR M4DWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G2V2lEPTB;Mj6wPVg5QSBizszN NHnZV5VUSU6JRWK=
TK10 NXnBdlRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CyPWlEPTB;Mj6xN|Q2QCBizszN NHizOlFUSU6JRWK=
CAL-39 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDaTWM2OD1{LkG0OFghKM7:TR?= NVL6SpBUW0GQR1XS
NCI-H2030 NGP0S29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjibpBKSzVyPUKuNVg6PzNiIN88US=> M2TkPXNCVkeHUh?=
HCT-116 NFL0ZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLhfHJnUUN3ME2yMlIzQTh2IDFOwG0> NYDJSopwW0GQR1XS
HTC-C3 M1;WU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO1[GNsUUN3ME2yMlI3QDJ2IDFOwG0> NX\EOYN{W0GQR1XS
TYK-nu NWLnZ2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwM{C5NFkhKM7:TR?= MVHTRW5ITVJ?
FADU MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrDUYFVUUN3ME2yMlMzOjl4IDFOwG0> MlPFV2FPT0WU
A431 NGrQSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwM{ewNlUhKM7:TR?= NUO1WmRGW0GQR1XS
TE-11 NXTiSYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwM{iwNVkhKM7:TR?= NFjad3NUSU6JRWK=
CAL-12T M{npb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPzd5lsUUN3ME2yMlQxPDF5IDFOwG0> NHzxW2VUSU6JRWK=
DB MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjOfIVKSzVyPUKuOFI5PjliIN88US=> MoLUV2FPT0WU
L-363 M1vBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HDZ2lEPTB;Mj60N|UxPyBizszN M4HOZXNCVkeHUh?=
MSTO-211H MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z1UmlEPTB;Mj62OlM6OSBizszN MUHTRW5ITVJ?
SK-UT-1 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3FN2JDUUN3ME2yMlcyPDB4IDFOwG0> MoPRV2FPT0WU
RPMI-8226 NVTp[IpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS5c|ZtUUN3ME2yMlc{OTZ2IDFOwG0> MVvTRW5ITVJ?
SF295 NVvTfmEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwN{SzNUAh|ryP NYLvNJdHW0GQR1XS
OS-RC-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL0OopKSzVyPUKuO|Y3PzNiIN88US=> M2\Eb3NCVkeHUh?=
SK-MEL-24 M1XSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr3PHVKSzVyPUKuO|gzOjRiIN88US=> M1XJfXNCVkeHUh?=
COR-L23 NX3NT3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILRfVdKSzVyPUKuO|k1PjRiIN88US=> NGDmPXhUSU6JRWK=
MHH-PREB-1 MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX5VXNVUUN3ME2yMlgxOTZzIDFOwG0> NVfrRY1ZW0GQR1XS
SK-N-DZ MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzlXIhKSzVyPUKuPFE3OzhiIN88US=> NVzLc4ZWW0GQR1XS
OMC-1 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP0eYVKSzVyPUKuPFUxODNiIN88US=> NIW0UmFUSU6JRWK=
SK-MEL-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfETWM2OD1{Lki5NlQ{KCEQvF2= M3zWZ3NCVkeHUh?=
SAS Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwOUm0NVUhKM7:TR?= NUW2[2xxW0GQR1XS
EPLC-272H NH;ZOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfzbWxuUUN3ME2zMlAxOjN3IDFOwG0> NXfUPWNOW0GQR1XS
8505C M4\LOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL3V4RjUUN3ME2zMlExOzBzIDFOwG0> NHT2b5dUSU6JRWK=
EW-11 NYDpTpRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrpZ4VKSzVyPUOuNVQzPzdiIN88US=> NY\lVVBoW0GQR1XS
YKG-1 NXXNRmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzKTWM2OD1|LkG0O|A3KCEQvF2= MnPvV2FPT0WU
EC-GI-10 MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jnZ2lEPTB;Mz6xO|I3OyBizszN MUfTRW5ITVJ?
SK-LU-1 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHzWFBUUUN3ME2zMlE5PDF6IDFOwG0> NXWyXIk3W0GQR1XS
P30-OHK MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwMkCxNVchKM7:TR?= NHLWR3lUSU6JRWK=
T-24 NVjIUoJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnFd4M6UUN3ME2zMlIyQDF2IDFOwG0> M3\iWHNCVkeHUh?=
HSC-2 NH7NZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwMkKyN|IhKM7:TR?= MYTTRW5ITVJ?
SK-MES-1 NH3hZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNwMkS4NlkhKM7:TR?= NWLZb|BCW0GQR1XS
SW48 NIW1boxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNwMkW0PFYhKM7:TR?= M2fPS3NCVkeHUh?=
ME-180 NWe1XHY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNwMk[wOVEhKM7:TR?= NFu4NGZUSU6JRWK=
NCI-H2009 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XiTWlEPTB;Mz6yPVAyKCEQvF2= NHnQXWJUSU6JRWK=
HL-60 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPYbVRKSzVyPUOuNlkyOyBizszN Mk\GV2FPT0WU
NCI-N87 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzsclRKSzVyPUOuN|AyPzJiIN88US=> NUDYVHJJW0GQR1XS
GMS-10 NV;2OGM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwM{SwPFYhKM7:TR?= Moq1V2FPT0WU
SCH M1\RcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNwNEC4OFQhKM7:TR?= MnjPV2FPT0WU
C-33-A NYXlbmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPQZ3dLUUN3ME2zMlQyPDJzIDFOwG0> M13HOnNCVkeHUh?=
NCI-H1703 M1\BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfvSJlKSzVyPUOuOFE5OTJiIN88US=> NY[zW29qW0GQR1XS
A427 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG2TWM2OD1|LkS2NVI1KCEQvF2= M{TsbHNCVkeHUh?=
MOLT-4 NYXFZ5BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTNwNEixPVkhKM7:TR?= MmnCV2FPT0WU
NCI-H1792 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKyXWFKSzVyPUOuOFk5ODJiIN88US=> MYTTRW5ITVJ?
NCI-H1650 NX:1c|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzwVnlTUUN3ME2zMlU4OjliIN88US=> NFHQOFFUSU6JRWK=
H-EMC-SS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDCSVdKSzVyPUOuOVg2PjliIN88US=> MnnpV2FPT0WU
SW982 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LlXGlEPTB;Mz61PFgzQSBizszN MlHXV2FPT0WU
DSH1 NHPOU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV35OIxMUUN3ME2zMlY1OTJ{IDFOwG0> MU\TRW5ITVJ?
NOS-1 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHpcoJKSzVyPUOuOlQzPzZiIN88US=> NInOXnVUSU6JRWK=
BT-549 NEKwSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNwNke4OVQhKM7:TR?= M1S4PXNCVkeHUh?=
HuCCT1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwN{SxO|chKM7:TR?= Mn;sV2FPT0WU
NCI-H1755 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwOU[5O|EhKM7:TR?= NY[0UGM3W0GQR1XS
KYSE-450 MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnvd2ZwUUN3ME2zMlk3QTl5IDFOwG0> MYfTRW5ITVJ?
MIA-PaCa-2 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfUTWM2OD1|Lkm3NlkhKM7:TR?= Ml7WV2FPT0WU
U-266 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXhRphKSzVyPUOuPVc1QDFiIN88US=> NGnleZZUSU6JRWK=
Mewo M1yyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XQVGlEPTB;ND6wOlM3OSBizszN NIfQbXpUSU6JRWK=
KYSE-520 M3;sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfQN4FTUUN3ME20MlA6Pzl7IDFOwG0> MVTTRW5ITVJ?
MN-60 NUKxRYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRwMUC1NFEhKM7:TR?= M4LjT3NCVkeHUh?=
Ramos-2G6-4C10 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRwMU[3N|khKM7:TR?= Mmr6V2FPT0WU
SK-MEL-1 NWrq[lRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DseGlEPTB;ND6xPFY6PSBizszN MV;TRW5ITVJ?
ABC-1 NX\4NXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGexfo1KSzVyPUSuNlM{OzNiIN88US=> MlzZV2FPT0WU
CAKI-1 NEP1cWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPjTWM2OD12LkK0OVcyKCEQvF2= MoLIV2FPT0WU
HOS MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHsTWM2OD12LkK5NVQyKCEQvF2= NIrJPY1USU6JRWK=
SN12C NGrIWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXkTWM2OD12LkO0NlQ1KCEQvF2= NF3yUJFUSU6JRWK=
NB13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvhc206UUN3ME20MlM4OzV3IDFOwG0> NWLkUVJbW0GQR1XS
M14 NHv6OIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRwNEi3PVIhKM7:TR?= NXn4fmdwW0GQR1XS
GP5d NV3D[29oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO2TWM2OD12LkWwNVIhKM7:TR?= NVL3cYlqW0GQR1XS
NCI-H720 NHPoUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRwNUO2NVIhKM7:TR?= Mn;zV2FPT0WU
D-423MG MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwNUO5NlQhKM7:TR?= MVPTRW5ITVJ?
ChaGo-K-1 M2G0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PkZ2lEPTB;ND61PVU2QSBizszN NFHB[oNUSU6JRWK=
MEL-HO NEL6d4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTRwNkGyOlEhKM7:TR?= MVTTRW5ITVJ?
MHH-ES-1 NX;weHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTRwNkK0NVEhKM7:TR?= NYT4WI1LW0GQR1XS
KYSE-270 M1TVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmwZ4RKSzVyPUSuOlUyOjZiIN88US=> MYTTRW5ITVJ?
GI-ME-N NGHWbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLBTWM2OD12LkexNlkyKCEQvF2= NYjrZlhxW0GQR1XS
HOP-92 M3v1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHSTWM2OD12LkixN|c6KCEQvF2= MnTkV2FPT0WU
MKN1 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXBTWM2OD12LkizPVE1KCEQvF2= MoPkV2FPT0WU
ML-2 NHHFWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLKTWM2OD12Lki1OlI3KCEQvF2= MlfKV2FPT0WU
RO82-W-1 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL2dVBKSzVyPUSuPVI6QCBizszN M4LDXHNCVkeHUh?=
G-361 NUXsdVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTVwMEGwNFMhKM7:TR?= M3HwNXNCVkeHUh?=
HC-1 NWK1WGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF6zPHVKSzVyPUWuNFMzQTFiIN88US=> M3fmVXNCVkeHUh?=
EW-24 NHX3VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLLTWM2OD13LkC0NFM5KCEQvF2= M{\2[XNCVkeHUh?=
HuP-T4 M2LjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj1TWM2OD13LkG0N|M1KCEQvF2= MoTmV2FPT0WU
8-MG-BA NIq2SlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LhRmlEPTB;NT6zOFI5KCEQvF2= NHrZ[HpUSU6JRWK=
HGC-27 NYjUfWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi2TWM2OD13LkO3OlgzKCEQvF2= Mn\0V2FPT0WU
TE-12 NYG0XGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTVwNEG1PFUhKM7:TR?= NXjuZW93W0GQR1XS
GT3TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTVwNESyNVIhKM7:TR?= MVfTRW5ITVJ?
DOHH-2 M4r5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rZU2lEPTB;NT60OVk5PiBizszN NILnT4FUSU6JRWK=
Ca-Ski MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrtVYtKSzVyPUWuOFYyOTViIN88US=> MV;TRW5ITVJ?
A172 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfNRm46UUN3ME21MlU1QTJ3IDFOwG0> M37kPXNCVkeHUh?=
EGI-1 NYDOdow2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET4WmRKSzVyPUWuOVg6OzhiIN88US=> MlrUV2FPT0WU
MZ2-MEL NVr2eFllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVwNkG0PFYhKM7:TR?= NYLnOYprW0GQR1XS
SW1710 NXvCT213T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjYdXNKSzVyPUWuOlkxQTFiIN88US=> M1m5O3NCVkeHUh?=
HT-144 NXnWfZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG2TWM2OD13LkeyOlg2KCEQvF2= M2HoN3NCVkeHUh?=
PA-1 M4\ueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwOEG4PVMhKM7:TR?= NGHS[GxUSU6JRWK=
HCC1937 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfjWIlKSzVyPUWuPFM6OjliIN88US=> NYnBd5pYW0GQR1XS
SK-OV-3 M4TrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTVwOUGxNlEhKM7:TR?= MnzZV2FPT0WU
K5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfPb5l2UUN3ME22MlA2OTdiIN88US=> MYrTRW5ITVJ?
NMC-G1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfpeW5KSzVyPU[uNFc4QTdiIN88US=> M4jKfHNCVkeHUh?=
MDA-MB-361 M{W3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rPUGlEPTB;Nj6wPVI3OSBizszN MXrTRW5ITVJ?
EKVX MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n2W2lEPTB;Nj6xN|UxOSBizszN M1;ySHNCVkeHUh?=
ES7 NGG5[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDx[XdKSzVyPU[uNVYyOTViIN88US=> MmXUV2FPT0WU
KS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPYWJFYUUN3ME22MlE4QTl|IDFOwG0> MUnTRW5ITVJ?
NCI-H661 NG\DWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwMUiwPFEhKM7:TR?= MXjTRW5ITVJ?
ES8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[zTWM2OD14LkG4NFgzKCEQvF2= NHzlcGFUSU6JRWK=
NCI-H23 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnq[oJ[UUN3ME22MlIyQDF4IDFOwG0> NVmyfFVTW0GQR1XS
T47D M2LEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrrTWM2OD14LkK2OFU4KCEQvF2= M3zCPHNCVkeHUh?=
A2780 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3aTWM2OD14LkO3O|AyKCEQvF2= MXrTRW5ITVJ?
SCC-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nycWlEPTB;Nj60N|U3OSBizszN NHXNdJBUSU6JRWK=
VA-ES-BJ M1uze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K2cWlEPTB;Nj65O|A1OyBizszN NFjzdnJUSU6JRWK=
no-11 M1XZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPHfGZKUUN3ME23MlE3PDFiIN88US=> MVvTRW5ITVJ?
KU-19-19 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\JTWM2OD15LkG2OFc3KCEQvF2= MUPTRW5ITVJ?
MKN45 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTdwMUi2PVkhKM7:TR?= NI\UfWtUSU6JRWK=
SCC-25 NUnQdJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ibmlEPTB;Nz6yN|QyPCBizszN NF3ieoZUSU6JRWK=
ETK-1 NFfHSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPYTWM2OD15LkK1OVE1KCEQvF2= NVrvTmMxW0GQR1XS
COR-L88 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTdwMkmzNVkhKM7:TR?= MXvTRW5ITVJ?
8305C NUn0Z4N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrlbVhKSzVyPUeuN|I1QTJiIN88US=> MX7TRW5ITVJ?
Detroit562 NXfaXGl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTdwM{K1NFYhKM7:TR?= NEXOU5dUSU6JRWK=
SNU-449 NW\jWGxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnSRmhKSzVyPUeuN|c3PTFiIN88US=> NFKwV4dUSU6JRWK=
A704 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT1TWM2OD15LkO4Nlc5KCEQvF2= M4racXNCVkeHUh?=
D-502MG NY[wOVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTdwM{i0O|MhKM7:TR?= M3n1bHNCVkeHUh?=
NCI-H2228 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2noSGlEPTB;Nz60NVQ2QCBizszN MoP3V2FPT0WU
CHP-212 NYDseWRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXidJBoUUN3ME23MlUyQDl4IDFOwG0> NWTmRnJRW0GQR1XS
VMRC-RCZ M1y3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3aO3E6UUN3ME23MlU6ODZ4IDFOwG0> MXfTRW5ITVJ?
RPMI-2650 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTvTWM2OD15LkewN|EzKCEQvF2= M2C3W3NCVkeHUh?=
HCC2218 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfrPGpHUUN3ME23MlczOjV6IDFOwG0> NYizUYdIW0GQR1XS
GCT M1fvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLvd|BKSzVyPUeuPFIyPzJiIN88US=> NYW3SlQ4W0GQR1XS
SW780 NXH4b2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{THSGlEPTB;Nz65PVA3KCEQvF2= MnG4V2FPT0WU
KMOE-2 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRThwMESwO{Ah|ryP MnzhV2FPT0WU
KYSE-180 M2PiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRThwMEi2OFghKM7:TR?= MmnoV2FPT0WU
TE-1 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXHTWM2OD16LkGxNFU4KCEQvF2= MWfTRW5ITVJ?
OAW-42 NIm5boVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rZcGlEPTB;OD6yOVQ6PiBizszN NYrIUWdpW0GQR1XS
VM-CUB-1 NGTx[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRThwMkizOlQhKM7:TR?= MUnTRW5ITVJ?
ECC10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrMXoxKSzVyPUiuNlg{QTdiIN88US=> MnWwV2FPT0WU
SW1573 M3O1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRThwNES0OlUhKM7:TR?= NGrmboRUSU6JRWK=
NCI-H1299 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;2OlhKSzVyPUiuOVk4PzRiIN88US=> MWrTRW5ITVJ?
ALL-PO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRThwNk[1PVchKM7:TR?= MWnTRW5ITVJ?
OVCAR-5 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nWRmlEPTB;OD63O|YzPSBizszN NFrVRlFUSU6JRWK=
NCI-SNU-5 NXfuc3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRThwOEOwNFEhKM7:TR?= MVrTRW5ITVJ?
NCI-H2342 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljYTWM2OD16LkizNVAyKCEQvF2= M2HhcXNCVkeHUh?=
RPMI-7951 NFfmc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnHS2d4UUN3ME24Mlg1OTV5IDFOwG0> MXHTRW5ITVJ?
RCM-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\VTWM2OD17LkC4NVQ2KCEQvF2= MkHVV2FPT0WU
Daoy MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILMOYlKSzVyPUmuNVIxOjhiIN88US=> M4fOW3NCVkeHUh?=
HCC1395 NEHWV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofvTWM2OD17LkOwPFk3KCEQvF2= M3vQUHNCVkeHUh?=
786-0 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37FTGlEPTB;OT6zOlAzPiBizszN NF3WXYhUSU6JRWK=
GAMG MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnUTWM2OD17Lk[1OVM1KCEQvF2= MYTTRW5ITVJ?
HCC1954 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PuUWlEPTB;OT64OVg2QSBizszN M{nhdHNCVkeHUh?=
NCI-H1838 NFTYRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq5SJc5UUN3ME25MlkxOzdzIDFOwG0> MVLTRW5ITVJ?
SW620 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTlwOUWzOVchKM7:TR?= M3nxT3NCVkeHUh?=
NCI-H358 NIrt[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFyLkSxPVchKM7:TR?= NUPzb2VCW0GQR1XS
NCI-H1793 NGOwXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixcZF6UUN3ME2xNE41OjR6IDFOwG0> Mo\aV2FPT0WU
NCI-H1666 NIj4PYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETNbZRKSzVyPUGwMlQ{PTViIN88US=> NEPOS3dUSU6JRWK=
MZ7-mel MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ezT2lEPTB;MUCuOFc2OyBizszN MoTZV2FPT0WU
MDA-MB-175-VII Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFyLk[zPVYhKM7:TR?= NHH3T|ZUSU6JRWK=
COLO-829 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFyLkiwNFQhKM7:TR?= M3i2fHNCVkeHUh?=
RVH-421 NEeyXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Xx[GlEPTB;MUGuNVUzKCEQvF2= NVfw[FhnW0GQR1XS
A549 NInZfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm4Zo9GUUN3ME2xNU4zPDd6IDFOwG0> NGTZRlFUSU6JRWK=
DJM-1 NXmyWGF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHqeWszUUN3ME2xNU4{QDN|IDFOwG0> Mn\NV2FPT0WU
IST-MEL1 M{fD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHnSpZ{UUN3ME2xNU44OzF7IDFOwG0> MVnTRW5ITVJ?
BEN MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjw[2lJUUN3ME2xNU44PDB{IDFOwG0> MnPjV2FPT0WU
KM12 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFzLkmwPVEhKM7:TR?= NVL6Row4W0GQR1XS
HuO9 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF{LkC2OlYhKM7:TR?= NGjEfIhUSU6JRWK=
U-2-OS M4fNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX4TWM2OD1zMj6wPFk{KCEQvF2= M3fwRXNCVkeHUh?=
RH-1 NI\qdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLwTWM2OD1zMj60OFczKCEQvF2= MVLTRW5ITVJ?
NCI-H1048 M{XGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LOWGlEPTB;MUKuOVUxPiBizszN NGja[lRUSU6JRWK=
Mo-T NE[3N3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rSdmlEPTB;MUKuO|MxPyBizszN MUXTRW5ITVJ?
KYSE-150 M3TzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF{Lke0OVUhKM7:TR?= M{nEfnNCVkeHUh?=
A388 NIfie5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF{Lke3NVMhKM7:TR?= NHv2XJJUSU6JRWK=
NCI-SNU-1 M2\IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInv[I9KSzVyPUGyMlgxPDZiIN88US=> NVSxNodFW0GQR1XS
HEL NYWzbmM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHLPY1[UUN3ME2xNk45OjF{IDFOwG0> MoewV2FPT0WU
UM-UC-3 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF{Lki4O|QhKM7:TR?= MnfFV2FPT0WU
TGBC24TKB MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfR[HQ3UUN3ME2xN{4xOjZ5IDFOwG0> MXfTRW5ITVJ?
SW626 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF|LkK0PFUhKM7:TR?= MWLTRW5ITVJ?
ES6 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnSTolvUUN3ME2xN{4zPTF{IDFOwG0> NHfR[odUSU6JRWK=
NCI-H2029 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\CTWM2OD1zMz64NVA5KCEQvF2= NE\DSGFUSU6JRWK=
RXF393 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXOTWM2OD1zMz65PVI4KCEQvF2= M1HXSXNCVkeHUh?=
HMV-II MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPPXIJ1UUN3ME2xOE4xPzhiIN88US=> NUXFToR7W0GQR1XS
EW-22 NVXwNIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TaemlEPTB;MUSuNVUxOiBizszN MX\TRW5ITVJ?
AsPC-1 M3TNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF2LkW2OEAh|ryP NFT2XVJUSU6JRWK=
COLO-678 NXTJO3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[2TWM2OD1zND63NlcyKCEQvF2= NWfHe3ZJW0GQR1XS
HCT-15 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfHWpdTUUN3ME2xOE45QDV3IDFOwG0> NYmwNoR[W0GQR1XS
HCE-T NXvlOI9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvOfo9KSzVyPUG0Mlg5PzRiIN88US=> NWLiUIhyW0GQR1XS
SF539 NWfLbVhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHznN4tKSzVyPUG1MlA3PDNiIN88US=> M3q0c3NCVkeHUh?=
AU565 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTWTWM2OD1zNT6yNFk3KCEQvF2= Mk[yV2FPT0WU
JVM-2 NH\EfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF3LkK2PFEhKM7:TR?= M1fjdnNCVkeHUh?=
CaR-1 NF;Id5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fpN2lEPTB;MUWuOFQyOiBizszN MV7TRW5ITVJ?
23132-87 NV\2eWo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PPT2lEPTB;MUWuPFQ6PSBizszN MUfTRW5ITVJ?
A673 M1;JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTzVIJKSzVyPUG1Mlk3OzZiIN88US=> NW\NN5d[W0GQR1XS
KYSE-410 NUDtNHhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXybFZoUUN3ME2xOk4xOjliIN88US=> MX7TRW5ITVJ?
TE-9 NXXSW|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorOTWM2OD1zNj6wOlIhKM7:TR?= MYLTRW5ITVJ?
LU-139 M13hWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nndGlEPTB;MU[uNVgzOyBizszN NI\OZZpUSU6JRWK=
GCIY Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C2SWlEPTB;MU[uNVkyPiBizszN M{Tu[XNCVkeHUh?=
JEG-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj1XINKSzVyPUG2MlI2KCEQvF2= NVTXTI5ZW0GQR1XS
RT-112 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3RTWM2OD1zNj60NVQ{KCEQvF2= NGfk[plUSU6JRWK=
COLO-680N MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvF[Y9KSzVyPUG2MlUyODhiIN88US=> NH3w[5NUSU6JRWK=
LU-134-A NV;xOoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyzOWhFUUN3ME2xOk46QDl|IDFOwG0> M{H4VXNCVkeHUh?=
MFM-223 NXP5UJUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6zd4ZYUUN3ME2xO{4yPTN3IDFOwG0> NXjv[oh[W0GQR1XS
SF126 NH6zbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvZNIZXUUN3ME2xO{4yPzBzIDFOwG0> MnL5V2FPT0WU
NCI-H28 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj0TWM2OD1zNz6yNFY3KCEQvF2= MmTMV2FPT0WU
BFTC-905 M4DFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP6c413UUN3ME2xO{41QDN{IDFOwG0> M1;1dXNCVkeHUh?=
SCC-9 NWi5RYxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF5Lk[yPFUhKM7:TR?= NWfLW|RPW0GQR1XS
KNS-62 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnflTWM2OD1zNz62OlI6KCEQvF2= NVi3W453W0GQR1XS
Hs-578-T MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDYeVZKSzVyPUG3MlgyPDliIN88US=> M3vwNHNCVkeHUh?=
D-336MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvJS2dIUUN3ME2xO{45Ojl2IDFOwG0> NI\ReJFUSU6JRWK=
NCI-H82 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF6LkCxPFMhKM7:TR?= NGXxbZNUSU6JRWK=
EFM-19 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF6LkC1O|chKM7:TR?= MnWxV2FPT0WU
TGBC11TKB NFLSZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXKN5R{UUN3ME2xPE4yODJzIDFOwG0> MUHTRW5ITVJ?
HEC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjsdXJpUUN3ME2xPE4zQTF6IDFOwG0> MkjGV2FPT0WU
HuP-T3 NIDXT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF6LkW5NlkhKM7:TR?= M4Pne3NCVkeHUh?=
SF268 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T4T2lEPTB;MUiuOlcxOiBizszN NUPjVHFoW0GQR1XS
COLO-792 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;nTWM2OD1zOD63PVk4KCEQvF2= Mn\nV2FPT0WU
HLE NV\DbYFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfvTWM2OD1zOD64N|MyKCEQvF2= NF2wU5pUSU6JRWK=
A204 M1m5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PIVmlEPTB;MUiuPVE3PCBizszN MXrTRW5ITVJ?
CAL-72 NYPxU2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\CTWM2OD1zOT6wPFc4KCEQvF2= NH;EU4VUSU6JRWK=
U031 NEDNbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHRTWM2OD1zOT60PVA6KCEQvF2= M2LOXXNCVkeHUh?=
FTC-133 M4rDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPWTWM2OD1zOT65N|A1KCEQvF2= MlTkV2FPT0WU
SK-MEL-28 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPEZmRvUUN3ME2yNE4{PzZzIDFOwG0> NV\rV|lkW0GQR1XS
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfuTWM2OD1{MD60Olk6KCEQvF2= MnvQV2FPT0WU
HCC2998 NYG2cnQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJzLkO5NlYhKM7:TR?= NFH3NoxUSU6JRWK=
GOTO Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn3TWM2OD1{MT60PFUhKM7:TR?= MVjTRW5ITVJ?
AGS NHi4b29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH5OpZKSzVyPUKxMlg1PTFiIN88US=> NGnMeW9USU6JRWK=
EW-13 M4fx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnJfIc4UUN3ME2yNk4yODJ{IDFOwG0> M1SyZXNCVkeHUh?=
P12-ICHIKAWA Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DGfGlEPTB;MkKuNVYxOyBizszN MXXTRW5ITVJ?
NCI-H1395 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ{LkK5NFchKM7:TR?= Ml\MV2FPT0WU
A2058 M{LJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjt[HBLUUN3ME2yNk41OzRiIN88US=> NWPKVpNrW0GQR1XS
SH-4 NVTvOoJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ{LkewOFUhKM7:TR?= MV\TRW5ITVJ?
DoTc2-4510 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ|Lk[0O|IhKM7:TR?= MULTRW5ITVJ?
MMAC-SF MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnZNmhyUUN3ME2yN{43QTFzIDFOwG0> MXLTRW5ITVJ?
NCI-H510A NH2yUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPvdGE3UUN3ME2yN{44QTN7IDFOwG0> M4HWVnNCVkeHUh?=
HDLM-2 NXvUeWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ2LkG0OkAh|ryP M{\uT3NCVkeHUh?=
KINGS-1 NWXEVVlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnrV2tFUUN3ME2yOE4zPDJiIN88US=> MojpV2FPT0WU
NCI-H1648 M3zBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm2UmFsUUN3ME2yOE41ODJ2IDFOwG0> M3;Ob3NCVkeHUh?=
HCC1187 NGn6U4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HnNmlEPTB;MkWuNFI{PSBizszN NF3tW45USU6JRWK=
BALL-1 M2nLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHSTWM2OD1{NT6yNFYzKCEQvF2= MXjTRW5ITVJ?
SBC-1 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTibGVUUUN3ME2yOU4zQTl|IDFOwG0> NVPVNGJ1W0GQR1XS
BFTC-909 NVz4SpQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ3LkO1OVEhKM7:TR?= NUPJV4llW0GQR1XS
MOLT-13 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjVd|hkUUN3ME2yOU43PzR2IDFOwG0> M1q5SHNCVkeHUh?=
SW1990 NGeyUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ3Lkm2OVUhKM7:TR?= NEToNm9USU6JRWK=
DK-MG M3fjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDK[|BKSzVyPUK2MlA1PDNiIN88US=> NH[zSmdUSU6JRWK=
TE-8 NH2zWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJ4LkC2OlghKM7:TR?= M2T4d3NCVkeHUh?=
Becker M{\jUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ4LkG1O|QhKM7:TR?= MY\TRW5ITVJ?
KYSE-70 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvjTWM2OD1{Nj61N|E4KCEQvF2= NXrLPZo4W0GQR1XS
MKN7 NVn6dWNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vY[2lEPTB;MkeuO|Q4QSBizszN M4LDd3NCVkeHUh?=
D-392MG NGXDbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDMZpdmUUN3ME2yO{44Pjl2IDFOwG0> M2f3VXNCVkeHUh?=
NH-12 NYrEcnZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXXTWM2OD1{OD6xNlI6KCEQvF2= Ml\5V2FPT0WU
EW-18 NEPv[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\iTGlEPTB;MkiuNlIyQCBizszN NX;nZXdqW0GQR1XS
LCLC-97TM1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ6LkK3OlIhKM7:TR?= NFr4fpBUSU6JRWK=
NCI-H1770 NXW0VYpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1{OD6zOVY3KCEQvF2= MXrTRW5ITVJ?
BT-20 NVvBVZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TYSGlEPTB;MkiuN|Y5PSBizszN NEW5[WxUSU6JRWK=
DBTRG-05MG M4fMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfNUXM4UUN3ME2yPE41QDN6IDFOwG0> MkLOV2FPT0WU
HPAF-II MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPSTWM2OD1{OD63O|khKM7:TR?= MnX0V2FPT0WU
SW837 NIfYc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rhSmlEPTB;MkmuN|M5PSBizszN MXrTRW5ITVJ?
647-V NYixNFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLueItKSzVyPUK5MlcxODNiIN88US=> NGPMdlJUSU6JRWK=
J82 M4jRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ7LkiwNVMhKM7:TR?= MkfKV2FPT0WU
MC116 NXG3Z3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHYTWM2OD1|MD6wO|M{KCEQvF2= M3HF[3NCVkeHUh?=
NCI-H69 NIfZNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPCZ|g4UUN3ME2zNE43ODl|IDFOwG0> M1fn[nNCVkeHUh?=
NB6 NVz5WWhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\meoFKSzVyPUOxMlM3OjliIN88US=> NFjS[pBUSU6JRWK=
CAL-120 NWDOWIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HGVGlEPTB;M{KuOFMyPyBizszN NY\wRlduW0GQR1XS
U-87-MG MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jkV2lEPTB;M{OuNFI2OSBizszN NWjDfoh6W0GQR1XS
NCI-H1304 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHkZVNKSzVyPUOzMlA{PTRiIN88US=> M{nhPHNCVkeHUh?=
YH-13 M3jFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nScWlEPTB;M{OuNlU{PSBizszN Mlf6V2FPT0WU
RMG-I Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4CwV2lEPTB;M{OuOFI5PSBizszN MlnJV2FPT0WU
LU-65 NUPoXppQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELUXZFKSzVyPUO0MlE1ODhiIN88US=> MnThV2FPT0WU
GB-1 NHPiemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\1ZWpKSzVyPUO1MlA4OjliIN88US=> MWXTRW5ITVJ?
DU-4475 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrGWnNKSzVyPUO1MlE2PTNiIN88US=> NIewO|FUSU6JRWK=
SBC-5 NWHFWlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;6enhPUUN3ME2zOk42QTB{IDFOwG0> M4\3bnNCVkeHUh?=
OE33 NXfmUJkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHXdI1KSzVyPUO3Mlc2PzdiIN88US=> MX3TRW5ITVJ?
C8166 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofaTWM2OD1|OD61NlY4KCEQvF2= M2DDXnNCVkeHUh?=
COLO-684 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PU[2lEPTB;M{iuO|QzQCBizszN M3;QPHNCVkeHUh?=
NCI-H1155 NEXXOINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TFfmlEPTB;M{muNFQ4OSBizszN MmfnV2FPT0WU
ATN-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHwNG1kUUN3ME2zPU44Pzl{IDFOwG0> NUftS4tSW0GQR1XS
KARPAS-299 M3XFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC2TWM2OD1|OT64N|khKM7:TR?= MkjuV2FPT0WU
KNS-81-FD MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRyLkO2NFQhKM7:TR?= MXvTRW5ITVJ?
NCI-H1563 M1K3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTRzLkWwN|khKM7:TR?= MmTzV2FPT0WU
NB14 NHLDOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HibmlEPTB;NEKuO|I3OyBizszN MoPGV2FPT0WU
COLO-800 NVPxU4g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTR{Lki1NVchKM7:TR?= M3jTfHNCVkeHUh?=
MS-1 NGr5XYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj2TWM2OD12Mz6wOFg{KCEQvF2= MVHTRW5ITVJ?
OVCAR-8 M1jBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy5WHBKSzVyPUSzMlY5ODliIN88US=> M{HiO3NCVkeHUh?=
SK-PN-DW NFjSNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTR|Lki3O|YhKM7:TR?= NY\WPJhNW0GQR1XS
G-402 M3TlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfTR4tKSzVyPUSzMlkxODZiIN88US=> NH\BOnJUSU6JRWK=
NCI-H2291 M{\YV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLGVnZ6UUN3ME20OE45ODF5IDFOwG0> MXTTRW5ITVJ?
PC-3 M3XVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTR3LkiwNlMhKM7:TR?= NXnqdmtOW0GQR1XS
NCI-H1581 M3LSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[0TWM2OD12NT65PFg6KCEQvF2= NEfaSIpUSU6JRWK=
SW1116 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXmTWM2OD12Nz6wNVgzKCEQvF2= NEC5eY9USU6JRWK=
ZR-75-30 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfSO3duUUN3ME20O{4xOjN7IDFOwG0> NWHhRnVYW0GQR1XS
OCI-AML2 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K1[WlEPTB;NEeuNFkyQCBizszN Mmj0V2FPT0WU
MDA-MB-231 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;CTWM2OD12Nz62NlQ6KCEQvF2= NHHLXJJUSU6JRWK=
ES3 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTCW3VtUUN3ME20PE4{PTJ7IDFOwG0> M2nWZnNCVkeHUh?=
NCI-H630 NGfTN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXqTWM2OD12OT6xO|QzKCEQvF2= MoXlV2FPT0WU
OE19 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v5NGlEPTB;NEmuNlkxOiBizszN NVXPZ4t5W0GQR1XS
NCI-H1573 M2rwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTR7Lk[4OlEhKM7:TR?= M1PHSnNCVkeHUh?=
EW-1 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljWTWM2OD12OT65NFg1KCEQvF2= M3HBV3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]

Protocol

Kinase Assay:

[1]

+ Expand

The Src and Abl kinase assays:

The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.
Cell Research:

[2]

+ Expand
  • Cell lines: Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Nude female mice injected with K562 cells
  • Formulation: Suspended in 0.5% methocel/0.4% Tween 80
  • Dosages: ~150 mg/kg/day
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03023319 Recruiting Carcinoma, Non-Small-Cell Lung|Mesothelioma|Bladder Cancer|Ovarian Cancer|Peritoneal Cancer|Thymoma|Thymus Cancer|Uterine Cervical Cancer Nagla Karim|University of Cincinnati January 2017 Phase 1
NCT02810990 Recruiting Chronic Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto November 2016 Phase 2
NCT02906696 Recruiting Chronic Myelogenous Leukemia M.D. Anderson Cancer Center|Pfizer October 2016 Phase 2
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02921477 Enrolling by invitation Mild Cognitive Impairment|Dementia Neurological Associates of West Los Angeles|Pfizer September 2016 Phase 1
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can I give S1014 Bosutinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    For oral gavage, S1014 Bosutinib can be dissolved in 5% Tween 80+0.5% CMC Na at 30 mg/ml as a suspension.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) supplier | purchase Bosutinib (SKI-606) | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) manufacturer | order Bosutinib (SKI-606) | Bosutinib (SKI-606) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID